Free shipping on all orders over $ 500

Acalabrutinib

Cat. No. M5306

All AbMole products are for research use only, cannot be used for human consumption.

Acalabrutinib Structure
Synonym:

ACP-196

Size Price Availability Quantity
5mg USD 45 In stock
10mg USD 75 In stock
25mg USD 120 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

In vitro: In the in vitro signaling assay on primary human CLL cells, acalabrutinib inhibits tyrosine phosphorylation of downstream targets of ERK, IKB, and AKT. Acalabrutinib demonstrates higher selectivity for BTK with IC50 determinations on nine kinases with a cysteine residue in the same position as BTK. Importantly, unlike ibrutinib, acalabrutinib does not inhibit EGFR, ITK, or TEC. acalabrutinib has no effect on EGFR phosphorylation on tyrosine residues Y1068 and Y1173. Compared with ibrutinib, acalabrutinib has much higher IC50(>1000 nM) or virtually no inhibition on kinase activities of ITK, EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK, LCK, LYN, SRC, and YES1.

In vivo: oral administration of ACP-196 in mice results in dose-dependent inhibition of anti-IgM-induced CD86 expression in CD19+ splenocytes with an ED50 of 0.34 mg/kg compared to 0.91 mg/kg for ibrutinib. A similar model is used to compare the duration of Btk inhibition after a single oral dose of 25 mg/kg. ACP-196 inhibits CD86 expression >90% at 3h postdose.

Chemical Information
Molecular Weight 465.51
Formula C26H23N7O2
CAS Number 1420477-60-6
Solubility (25°C) 80 mg/mL in DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Wu J, et al. J Hematol Oncol. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.

[2] Byrd JC, et al. N Engl J Med. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

Related BTK Products
PCI-32765

PCI-32765 (Ibrutinib) is a potent, selective and orally bioavailable irreversible inhibitor of BTK with IC50 value of 0.46 nM.

Spebrutinib (AVL-292)

Spebrutinib (AVL-292) is an oral, potent and selective small molecule covalent inhibitor of Btk (IC50 < 0.5 nM).

CNX-774

CNX-774 is an irreversible, orally active, and highly selective BTK inhibitor with IC50 of <1 nM.

GDC-0834

GDC-0834 is a novel potent and selective BTK inhibitor with IC50 of 5.9 nM.

CGI1746

CGI1746 is a potent and highly selective small-molecule inhibitor of the Btk with IC50 of 1.9 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: Acalabrutinib, ACP-196 supplier, BTK, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.